文献速递乳腺癌

基于模拟模型的临床决策工具:识别21基因复发评分检测可能改变决策的患者

Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
PubMed 文献 · J Clin Oncol · 2021-07-12

研究开发并外部验证了一种独立于厂商的临床决策工具,整合临床病理特征、合并症和基因组信息,用于淋巴结阴性、激素受体阳性、HER2阴性早期乳腺癌女性。模型模拟1512种患者亚组,比较化疗内分泌治疗与内分泌治疗的10年远处复发风险、乳腺癌特异性死亡、其他原因死亡和生命年获益,结果显示模型能紧密重现两个独立数据集的观察率,可支持基因组检测和治疗讨论。

要点

  • 工具可估算不同临床病理特征和合并症下化疗内分泌治疗 vs 内分泌治疗的绝对获益。
  • 对于65-69岁、肿瘤≤2cm、中级别、轻度合并症患者,化疗内分泌治疗10年远处复发绝对降低1.3%,获得0.23生命年。
  • 若21基因复发评分为26+,绝对获益增至4.8%-5.5%。

核心结论

  • 经过验证的临床决策工具灵活、易于适应新疗法,可支持关于基因组检测和早期乳腺癌治疗的讨论。

研究设计与样本

  • 研究改编现有癌症干预与监测建模网络模拟模型,模拟1512个独特患者亚组,基于年龄、肿瘤大小、分级和合并症水平的所有可能组合,分别在有和无21基因复发评分下进行模拟。
  • 模型输入来自临床试验、大型美国队列研究、登记和索赔数据,并通过与两个独立来源的观察率比较进行外部验证。

主要发现

  • 在65-69岁、小肿瘤(≤2 cm)、中级别、轻度合并症女性中,化疗内分泌治疗 vs 内分泌治疗提供10年远处复发风险绝对降低1.3%,获得0.23生命年。
  • 该类患者具有28%概率为RS 16-20,18%概率为RS 21-25,11%概率为RS 26+。
  • 若检测且RS为16-20,化疗内分泌治疗将10年远处复发风险降至1%,获得0.20生命年,与未检测结果相似。
  • 若RS为26+,绝对获益增至4.8%-5.5%。
  • 模型紧密重现了两个独立数据集中的观察率。

关键数值与推荐

  • 对于65-69岁、肿瘤≤2 cm、中级别、轻度合并症女性:化疗内分泌治疗 vs 内分泌治疗的10年远处复发绝对降低1.3%,生命年获益0.23。
  • RS 16-20概率28%,RS 21-25概率18%,RS 26+概率11%。
  • 若RS 16-20,化疗内分泌治疗10年远处复发风险降至1%,生命年获益0.20。
  • 若RS 26+,绝对获益增至4.8%-5.5%。

临床怎么用

  • 临床决策工具可整合临床病理特征、合并症和基因组信息,辅助识别21基因复发评分检测可能改变治疗决策的患者。
  • 工具支持关于基因组检测和早期乳腺癌治疗的讨论,灵活适应新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a need for industry-independent decision tools that integrate clinicopathologic features, comorbidities, and genomic information for women with node-negative, invasive, hormone receptor-positive, human epidermal growth factor receptor-2-negative (early-stage) breast cancer. METHODS: We adapted an extant Cancer Intervention and Surveillance Modeling Network simulation model to estimate the 10-year risk of distant recurrence, breast cancer-specific mortality, other-cause mortality, and life-years gained with chemoendocrine versus endocrine therapy. We simulated outcomes for 1,512 unique patient subgroups based on all possible combinations of age, tumor size, grade, and comorbidity level; simulations were performed with and without 21-gene recurrence scores (RSs). Model inputs were derived from clinical trials, large US cohort studies, registry, and claims data. External validation was performed by comparing results to observed rates in two independent sources. We highlight results for one scenario where treatment choice may be uncertain. RESULTS: Chemoendocrine versus endocrine therapy in a 65-69-year-old woman with a small (≤ 2 cm), intermediate-grade tumor, and mild comorbidities provides a 1.3% absolute reduction in 10-year distant recurrence risk, with 0.23 life-years gained. With these tumor features, a woman like this will have a 28% probability of having an RS 16-20, 18% RS 21-25, and 11% RS 26+. If testing is done, and her RS is 16-20, chemoendocrine therapy reduces 10-year distant recurrence risk to 1%, with 0.20 life-years gained, a similar result as without testing. The absolute benefits would increase to 4.8%-5.5% if the RS was 26+. The model closely reproduced observed rates in both independent data sets. CONCLUSION: Our validated clinical decision tool is flexible, readily adaptable to include new therapies, and can support discussions about genomic testing and early breast cancer treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jayasekera J, Sparano JA, O'Neill S, et al. Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. J Clin Oncol. 2021. PMID: 34251881. doi:10.1200/JCO.21.00651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。